Increased apolipoprotein D dimer formation in alzheimer's disease hippocampus is associated with lipid conjugated diene levels

Journal of Alzheimer's Disease

Volumn 35, Issue 3, 2013, Pages 475-486

  Bhatia, Surabhi ^a,b,c   Jenner, Andrew M ^c   Li, Hongyun ^c   Ruberu, Kalani ^c   Spiro, Adena S ^c   Shepherd, Claire E ^a   Kril, Jillian J ^d   Kain, Nupur ^e   Don, Anthony ^e   Garner, Brett ^c  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Apolipoprotein D; lipid peroxidation; oxidative stress; protein dimerization

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN D; DIMER; ISOPROSTANE DERIVATIVE; LIPID; LIPID CONJUGATED DIENE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOCORTEX; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; NEOCORTEX; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TEMPORAL LOBE;

EID: 84880216377     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122278     Document Type: Article

References (56)

1. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
2. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
3. Masliah E (2008) Neuropathology: Alzheimer's in real time. Nature 451, 638-639.
4. Iqbal K, Grundke-Iqbal I (2011) Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathol 122, 543-549.
5. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-peptideassociated free radical oxidative stress. Free Radic Biol Med 32, 1050-1060.
6. Pratico D (2008) Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: Lights and shadows. Ann N Y Acad Sci 1147, 70-78.
7. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48, 136-144.
8. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767.
9. Pratico D, Uryu K, Leight S, Trojanoswki JQ, LeeVM(2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21, 4183-4187.
10. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134-147.
11. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71, 621S-629S.
12. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23, 655-664.
13. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23, 795-807.
14. Drake J, Link CD, Butterfield DA (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24, 415-420.
15. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58, 730-735.
16. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA (2012) Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging 33, 1034-1044.
17. Lovell MA, Xie C, Markesbery WR (2001) Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22, 187-194.
18. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146.
19. Pratico D, Lee VM-Y, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777-1783.
20. Karelson E, Bogdanovic N, Garlind A,Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, Zilmer M (2001) The cerebrocortical areas in normal brain aging and in Alzheimer's disease: Noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 26, 353-361.
21. Milne RW, Rassart E, Marcel YL (1993) Molecular biology of apolipoprotein D. Curr Opin Lipidol 4, 100-106.
22. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, Milne R (2000) Apolipoprotein D. Biochim Biophys Acta 1482, 185-198.
23. Bhatia S, Knoch B, Wong J, Kim WS, Else PL, Oakley AJ, Garner B (2012) Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein-D: Implications for lipid antioxidant activity and Alzheimer's disease. Biochem J 442, 713-721.
24. Navarro A, Tolivia J, Astudillo A, delValle E (1998) Pattern of apolipoprotein D immunoreactivity in human brain. Neurosci Lett 254, 17-20.
25. Navarro A, del Valle E, Juarez A, Martinez E, Ordonez C, Astudillo A, Tolivia J (2010) Apolipoprotein D synthesis progressively increases in frontal cortex during human lifespan. Age (Dordr) 32, 85-96.
26. Terrisse L, Poirier J, Bertrand P, Merched A, Visvikis S, Siest G, Milne R, Rassart E (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J Neurochem 71, 1643-1650.
27. Belloir B, Kovari E, Surini-Demiri M, Savioz A (2001) Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. J Neurosci Res 64, 61-69.
28. Thomas EA, Dean B, Pavey G, Sutcliffe JG (2001) Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: Implications for the pathophysiology of psychiatric disorders. Proc Natl Acad Sci U S A 98, 4066-4071.
29. Glockner F, Ohm TG (2003) Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype. Neuroscience 122, 103-110.
30. Ordonez C, Navarro A, Perez C, Astudillo A, Martinez E, Tolivia J (2006) Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol Histopathol 21, 361-366.
31. Kim WS,Wong J,Weickert CS,Webster MJ, Bahn S, Garner B (2009) Apolipoprotein-D expression is increased during development and maturation of the human prefrontal cortex. J Neurochem 109, 1053-1066.
32. Thomas EA, Laws SM, Sutcliffe JG, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN (2003) Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: No relation to apolipoprotein E expression or genotype. Biol Psychiatry 54, 136-141.
33. Desai PP, Ikonomovic MD, Abrahamson EE, Hamilton RL, Isanski BA, Hope CE, Klunk WE, DeKosky ST, Kamboh MI (2005) Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex. Neurobiol Dis 20, 574-582.
34. Martinez E, Navarro A, Ordonez C, Del Valle E, Tolivia J (2012) Amyloid-beta25-35 induces apolipoprotein D Synthesis and growth arrest in HT22 hippocampal cells. J Alzheimers Dis 30, 233-244.
35. Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, Gonzalez C, Bastiani MJ, Rassart E, Sanchez D (2008) Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7, 506-515.
36. Sanchez D, Lopez-Arias B, Torroja L, Canal I, Wang X, Bastiani MJ, Ganfornina MD (2006) Loss of glial lazarillo, a homolog of apolipoprotein D, reduces lifespan and stress resistance in Drosophila. Curr Biol 16, 680-686.
37. Walker DW, Muffat J, Rundel C, Benzer S (2006) Overexpression of a Drosophila homolog of apolipoprotein D leads to increased stress resistance and extended lifespan. Curr Biol 16, 674-679.
38. He X, Jittiwat J, Kim JH, Jenner AM, Farooqui AA, Patel SC, Ong WY (2009) Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainateinduced excitotoxic injury. Neurosci Lett 455, 183-186.
39. Oakley AJ, Bhatia S, Ecroyd H, Garner B (2012) Molecular dynamics analysis of apolipoprotein-D-lipid hydroperoxide interactions: Mechanism for selective oxidation of Met-93. PLoS One 7, e34057.
40. Harding AJ, Kril JJ, Halliday GM (2000) Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathol 99, 199-208.
41. Elliott DA, Tsoi K, Holinkova S, Chan SL, Kim WS, Halliday GM, Rye KA, Garner B (2011) Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging 32, 257-271.
42. Halliwell B, Gutteridge JMC (1999) Free Radicals in Biology and Medicine, Oxford University Press, Oxford, pp. 1-936.
43. Chia LS, Thompson JE, MoscarelloMA(1984) X-ray diffraction evidence for myelin disorder in brain from humans with Alzheimer's disease. Biochim Biophys Acta 775, 308-312.
44. Rosenthal RE, Chanderbhan R, Marshall G, Fiskum G (1992) Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starchconjugated deferoxamine. Free Radic Biol Med 12, 29-33.
45. Kutner MH, Nachtsheim CJ, Neter J (2004) Applied Linear Regression Models, 4th edition. McGraw-Hill Irwin, Chicago, pp. 1-701.
46. NIA (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18, S1-S2.
47. Gregory GC, Macdonald V, Schofield PR, Kril JJ, Halliday GM (2006) Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging 27, 387-393.
48. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189.
49. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800.
50. Fitzmaurice PS, Tong J, Yazdanpanah M, Liu PP, Kalasinsky KS, Kish SJ (2006) Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther 319, 703-709.
51. Harish G,Venkateshappa C, MahadevanA, Pruthi N, Srinivas Bharath MM, Shankar SK (2011) Glutathione metabolism is modulated by postmortem interval, gender difference and agonal state in postmortem human brains. Neurochem Int 59, 1029-1042.
52. Huang X, Atwood CS, Hartshorn MA,Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609-7616.
53. Butterfield DA, Bader Lange ML, Sultana R (2010) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim Biophys Acta 1801, 924-929.
54. Pratico D (2010) The neurobiology of isoprostanes and Alzheimer's disease. Biochim Biophys Acta 1801, 930-933.
55. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR (1999) Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 73, 1660-1666.
56. Montine TJ, Quinn J, Kaye J, Morrow JD (2007) F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci 33, 114-119.